How big is Castle Biosciences, Inc.?

As of Jun 18, Castle Biosciences, Inc. has a market capitalization of 535.29 million, with net sales of 347.08 million and a net profit of -5.07 million over the latest four quarters.

Market Cap: As of Jun 18, Castle Biosciences, Inc. has a market capitalization of 535.29 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Castle Biosciences reported net sales of 347.08 million and a net profit of -5.07 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 455.83 million and total assets of 553.92 million.

What does Castle Biosciences, Inc. do?

Castle Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $88 million and a net loss of $26 million as of March 2025. The company has a market cap of $535.29 million and does not pay dividends.

Overview:<BR>Castle Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 88 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 535.29 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: -0.95% <BR>Price to Book: 1.22<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Castle Biosciences, Inc.?

Is Castle Biosciences, Inc. overvalued or undervalued?

As of May 5, 2025, Castle Biosciences, Inc. is considered a risky investment due to its overvaluation, reflected in a Price to Book Value of 1.15, an unfavorable EV to EBITDA ratio of 8.54, a negative ROCE of -7.81%, and significant underperformance compared to the S&P 500.

As of 5 May 2025, the valuation grade for Castle Biosciences, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, given its current Price to Book Value of 1.15, an EV to EBITDA ratio of 8.54, and a negative ROCE of -7.81%. In comparison to peers, Castle's EV to EBITDA ratio is significantly less favorable than that of Atrion Corp., which has a ratio of 26.2211, and Silk Road Medical, Inc., with a ratio of -18.1243.<BR><BR>The stock has underperformed relative to the S&P 500, with a year-to-date return of -11.97% compared to the index's 12.22%, and a 1-year return of -22.73% versus 17.14% for the S&P 500. This trend reinforces the notion that Castle Biosciences, Inc. is overvalued in the current market context.

Is Castle Biosciences, Inc. technically bullish or bearish?

As of October 24, 2025, Castle Biosciences, Inc. has shifted to a bullish trend, supported by positive indicators like a bullish MACD, Bollinger Bands, and On-Balance Volume, despite mixed signals from the KST and a mildly bullish Dow Theory.

As of 24 October 2025, the technical trend for Castle Biosciences, Inc. has changed from mildly bullish to bullish. The key indicators driving this bullish stance include a bullish MACD on the weekly timeframe, bullish Bollinger Bands on both weekly and monthly timeframes, and a bullish daily moving average. Additionally, the On-Balance Volume (OBV) is bullish on both weekly and monthly charts. The KST shows a mixed signal with weekly bullishness but monthly bearishness, while Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes. There is no available return data to compare the company's performance against the S&P 500.